BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31482762)

  • 1. Prognostic value of
    Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
    Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
    Du M; Zhou F; Jin R; Hu Y; Mei H
    Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
    Yuan XQ; Peng L; Zeng WJ; Jiang BY; Li GC; Chen XP
    Medicine (Baltimore); 2016 May; 95(18):e3519. PubMed ID: 27149454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis.
    He W; Zhao C; Hu H
    Hematology; 2020 Dec; 25(1):494-501. PubMed ID: 33317419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
    Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
    PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
    Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
    Tie R; Zhang T; Fu H; Wang L; Wang Y; He Y; Wang B; Zhu N; Fu S; Lai X; Shi J; Huang H
    PLoS One; 2014; 9(6):e93353. PubMed ID: 24936645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of
    Li B; Zou D; Yang S; Ouyang G; Mu Q
    J Int Med Res; 2020 Mar; 48(3):300060519891013. PubMed ID: 31826693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
    Shou LH; Cao D; Dong XH; Fang Q; Wu Y; Zhang Y; Fei JP; Xu BL
    PLoS One; 2017; 12(2):e0171608. PubMed ID: 28158286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of
    Lin ME; Hou HA; Tsai CH; Wu SJ; Kuo YY; Tseng MH; Liu MC; Liu CW; Chou WC; Chen CY; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Lin CT; Tien HF
    Clin Epigenetics; 2018; 10():42. PubMed ID: 29619119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
    Arbab Jafari P; Ayatollahi H; Sadeghi R; Sheikhi M; Asghari A
    Hematology; 2018 Dec; 23(10):778-784. PubMed ID: 29757120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.
    Jin J; Hu C; Yu M; Chen F; Ye L; Yin X; Zhuang Z; Tong H
    PLoS One; 2014; 9(6):e100206. PubMed ID: 24936872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
    Zhang A; Wang S; Ren Q; Wang Y; Jiang Z
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis.
    Wu YC; Zhang XM; Zhu YD; Wu W
    Hematology; 2019 Dec; 24(1):60-69. PubMed ID: 30129389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
    Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
    Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
    Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.